<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018078</url>
  </required_header>
  <id_info>
    <org_study_id>ky-2021-7-9-1</org_study_id>
    <nct_id>NCT05018078</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer</brief_title>
  <official_title>The Fifth Medical Center of Chinese PLA General Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing 302 Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused pandemic since&#xD;
      outbreak in 2020. Patients with cancers may be at higher risk than those without cancer for&#xD;
      coronavirus disease 2019 (COVID-19). At present, limited data are available on the safety and&#xD;
      immunogenicity of COVID-19 vaccination for patients with cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-arm, open-label clinical trial. A total of 300 patients&#xD;
      with different cancers including hepatocellular carcinoma, breast cancer, lung cancer,&#xD;
      esophageal cancer, gastric cancer and colorectal cancer were included in this vaccination&#xD;
      study. All of the patients will further accept 12 months follow-up study after vaccination.&#xD;
      Safety and immunogenicity will be carefully recorded and detected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of coronavirus vaccine</measure>
    <time_frame>Within 2 months after the first dose of coronavirus vaccine</time_frame>
    <description>Occurence of adverse effects after COVID-19 vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of coronavirus vaccine</measure>
    <time_frame>Within 2 months after the first dose of coronavirus vaccine</time_frame>
    <description>Titers of anti-SARS-CoV-2 antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of coronavirus vaccine</measure>
    <time_frame>Within 13 months after the first dose of coronavirus vaccine</time_frame>
    <description>Occurence of adverse effects after COVID-19 vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of coronavirus vaccine</measure>
    <time_frame>Within 13 months after the first dose of coronavirus vaccine</time_frame>
    <description>Titers of anti-SARS-CoV-2 antibodies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Patients With Cancers</condition>
  <condition>COVID-19</condition>
  <condition>Vaccine</condition>
  <arm_group>
    <arm_group_label>Coronavirus vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental need to accept the coronavirus vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Coronavirus vaccine</intervention_name>
    <description>Coronavirus vaccine was inoculated on day 0 and day 25±3, respectively</description>
    <arm_group_label>Coronavirus vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age above 18 years&#xD;
&#xD;
          2. Patients with diagnosed cancers including hepatocellular carcinoma, breast cancer,&#xD;
             lung cancer, esophageal cancer, gastric cancer and colorectal cancer were included .&#xD;
&#xD;
          3. Patients who have received local or systemic anti-cancer therapies previously, and&#xD;
             have a stable condition with the ECOG score below 2.&#xD;
&#xD;
          4. The functions of multi-organs were normal or basically normal, and there are no&#xD;
             contraindications for vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with acute attack of chronic diseases.&#xD;
&#xD;
          2. Patients have history of convulsion, epilepsy, encephalopathy and psychosis.&#xD;
&#xD;
          3. Patients who are allergic to any component of the vaccine, or have a serious history&#xD;
             of vaccine allergy.&#xD;
&#xD;
          4. Pregnant or lactating women.&#xD;
&#xD;
          5. Sufferring serious cardiovascular diseases, such as arrhythmia, conduction block,&#xD;
             myocardial infarction, and severe hypertension can not be well controlled by drugs.&#xD;
&#xD;
          6. Patients have severe chronic diseases or diseases can not be controlled well during&#xD;
             the progress, such as asthma, diabetes, thyroid disease, etc. Congenital or acquired&#xD;
             angioedema / neuroedema.&#xD;
&#xD;
          7. Patients who are receiving immunomodulators treatment such as IL-2 or thymosin.&#xD;
&#xD;
          8. During vaccination, immunosuppressants, systemic cytotoxic drugs, immune checkpoint&#xD;
             inhibitors (PD-1 / PDL-1 / CTLA-4, etc.) and cell therapy, including NK cells,&#xD;
             cytokine induced killer cells, Dendritic cells、CTL and stem cells infusion are&#xD;
             required.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shu-juan Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing 302 Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fu-Sheng Wang, MD</last_name>
    <phone>8610-66933332</phone>
    <email>fswang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruonan Xu, MD</last_name>
    <phone>8610-66933333</phone>
    <email>xuruonan2004@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fu-Sheng Wang, MD</last_name>
      <phone>01066933328</phone>
      <email>fswang302@163.com</email>
    </contact>
    <investigator>
      <last_name>Fu-Sheng Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. Int J Infect Dis. 2020 Dec;101:314-322. doi: 10.1016/j.ijid.2020.10.011. Epub 2020 Oct 9. Review.</citation>
    <PMID>33045429</PMID>
  </reference>
  <reference>
    <citation>Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y, Xiong H, Wang C, Chen C, Xiong F, Zhang Y, Peng Y, Ge S, Zhen B, Yu T, Wang L, Wang H, Liu Y, Chen Y, Mei J, Gao X, Li Z, Gan L, He C, Li Z, Shi Y, Qi Y, Yang J, Tenen DG, Chai L, Mucci LA, Santillana M, Cai H. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020 Jun;10(6):783-791. doi: 10.1158/2159-8290.CD-20-0422. Epub 2020 Apr 28.</citation>
    <PMID>32345594</PMID>
  </reference>
  <reference>
    <citation>Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, Domingo-Vila C, Hayday TS, Graham C, Seow J, Abdul-Jawad S, Kamdar S, Harvey-Jones E, Graham R, Cooper J, Khan M, Vidler J, Kakkassery H, Sinha S, Davis R, Dupont L, Francos Quijorna I, O'Brien-Gore C, Lee PL, Eum J, Conde Poole M, Joseph M, Davies D, Wu Y, Swampillai A, North BV, Montes A, Harries M, Rigg A, Spicer J, Malim MH, Fields P, Patten P, Di Rosa F, Papa S, Tree T, Doores KJ, Hayday AC, Irshad S. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021 Jun;22(6):765-778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27.</citation>
    <PMID>33930323</PMID>
  </reference>
  <reference>
    <citation>Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T, Shorer Arbel Y, Scarfò L, Joffe E, Perry C, Ghia P. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.</citation>
    <PMID>33861303</PMID>
  </reference>
  <reference>
    <citation>Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021 Apr;74(4):944-951. doi: 10.1016/j.jhep.2021.01.032. Epub 2021 Feb 6. Review.</citation>
    <PMID>33563499</PMID>
  </reference>
  <reference>
    <citation>Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ; AASLD COVID-19 Vaccine Working Group. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology. 2021 Aug;74(2):1049-1064. doi: 10.1002/hep.31751.</citation>
    <PMID>33577086</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

